Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.60 |
| ▸ | PDE4A | P27815 | 15/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | VEGFA | P15692 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PDE1A | P54750 | 1/20 | 0.60 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498074 | 0.88 | PDE4A (0.52) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL6228022 | 0.86 | PDE4A (0.47) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL6228237 | 0.81 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6232341 | 0.78 | PDE4A (0.60) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL6229342 | 0.78 | PDE4A (0.60) | PDE4BPDE4APDE4CPDE4DALOX15 | |
| SCHEMBL6229565 | 0.78 | PDE4A (0.44) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL6227674 | 0.78 | PDE4A (0.60) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL3173894 | 0.77 | PDE4B (0.77) | PDE4BPDE4APDE4CPDE4DCYP3A4 | |
| SCHEMBL6232762 | 0.76 | PDE4A (0.62) | PDE4BPDE4APDE4CPDE4DMAPK1 | |
| SCHEMBL6233638 | 0.76 | PDE4A (0.50) | PDE4BPDE4APDE4CPDE4DVEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157084-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA CO (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| EP-0933366-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-6235739-B1 | ANTIINFLAMMATORY AGENTS; ANTIHISTAMINES; SKIN DISORDERS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0933366-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | PDE4B 1932/4885PDE4A 2167/4885PDE4C 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.